Name: Juvmo (tavapadon) in Parkinson's disease: Generic, brand name and therapeutic class of product
Published: 2026-09-27T21:44:59-04:00

Product information and disease description Product description Product information

Generic, brand name and therapeutic class of product

5 evidence topics · 4 sources

Manufacturer: AbbVie

“Marketed by: AbbVie Inc. North Chicago, IL 60064 U.S.A.” (opens the prescribing information at this quote)
“JUVMO and its design are trademarks of Cerevel Therapeutics, LLC, an AbbVie company.” (opens the prescribing information at this quote)

Brand name, generic name, and established pharmacologic class

“JUVMO™ (tavapadon) tablets, for oral use” (opens the prescribing information at this quote)
“JUVMO is a non-ergot dopamine agonist indicated for the treatment of Parkinson’s disease in adults.” (opens the prescribing information at this quote)
“The active ingredient of JUVMO is tavapadon, a non-ergot dopamine agonist.” (opens the prescribing information at this quote)

Chemical name, formula, and molecular weight

“The chemical name is (S)-1,5-dimethyl-6-(2-methyl-4-{[3-(trifluoromethyl) pyridin-2-yl]oxy}phenyl)pyrimidine- 2,4(1H,3H)-dione.” (opens the prescribing information at this quote)
“Its molecular formula is C19H16F3N3O3 and its molecular weight is 391.35 Daltons.” (opens the prescribing information at this quote)
“Tavapadon is a white to pale-yellow solid that is practically insoluble in water.” (opens the prescribing information at this quote)

Development codes

“One such noncatechol compound, tavapadon (also known as PF-06649751 and CVL-751), originally developed by Pfizer and later Cerevel Therapeutics (now part of AbbVie), recently showed promise for symptom relief in Parkinson’s disease, meeting the primary end point in a phase III study.” (opens the source at this quote in a new tab)

Therapeutic class: selective dopamine D1/D5 receptor partial agonist

“Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson's disease.” (opens the source at this quote in a new tab)

“Tavapadon, a highly selective partial agonist at D1 and D5 receptors, is being investigated for early through advanced PD” (opens the source at this quote in a new tab)